Company news
Youcare Pharmaceutical Group Co. Ltd. news in 2025
Youcare Pharmaceutical Group Co. Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
December 22, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY032 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration and FDA
December 19, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY031 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration
December 12, 2025
Announcement on Appointment of an Additional Director and Adjustment of Members of Special Committees of the Board of Directors
December 5, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY018 Inhalation Aerosol Obtaining Clinical Trial Approval from the National Medical Products Administration
December 2, 2025
Announcement on Voluntary Disclosure of Subholding YKYY018 Inhalation Aerosol's FDA Clinical Trial Approval
November 27, 2025
Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative
November 14, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY013 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration
November 5, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
October 29, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY013 Injection Obtaining Clinical Trial Approval from the FDA
September 22, 2025
Announcement on Resignation of Independent Director
September 11, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 28, 2025
Indicative Announcement on Completion of Transfer Registration for Partial Shares Held by Controlling Shareholders Subject to Judicial Auction and Change in Equity Shares Exceeding Integer Multiple of 5%
July 30, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY029 Injection Obtaining Clinical Trial Approval from the FDA
July 23, 2025
Announcement on Voluntary Disclosure of Subsidiary’s YKYY029 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration
July 17, 2025
Announcement on Progress of the 2nd Judicial Auction of a Portion of Company Shares Held by the Controlling Shareholder
July 15, 2025
Indicative Announcement on the 2nd Judicial Auction of Some Shares Held by Controlling Shareholder
June 27, 2025
Announcement on the Results of Shareholding Increase by Actual Controllers and Directors
June 16, 2025
Announcement on Reply to Inquiry Letter of 2024 Annual Report from Shanghai Stock Exchange
May 27, 2025
Announcement on Voluntary Disclosure of Ganciclovir for Injection Passing Consistency Evaluation of Quality and Efficacy of Generic Drugs
April 28, 2025
Announcement on Resolution of the 2024 Annual General Meeting
April 9, 2025
Announcement on 2024 Annual Profit Distribution Plan
March 14, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Voluntary Disclosure of FDA Approval for Clinical Trial of the Subsidiary's YKYY025 Injection
January 10, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
January 3, 2025